Lineage Cell Therapeutics (LCTX) Share-based Compensation Growth (3y) (2013 - 2026)
Lineage Cell Therapeutics (LCTX) Share-based Compensation Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -50.27% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -0.04% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 38.45% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 251.15 Mn | 188.44 Mn | 1.73 Mn | -66.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.15% |
| Dec 31, 2025 | -79.60% |
| Sep 30, 2025 | 6.70% |
| Jun 30, 2025 | 0.08% |
| Mar 31, 2025 | -76.15% |
| Sep 30, 2024 | 5.15% |
| Jun 30, 2024 | 11.36% |
| Mar 31, 2024 | 29.22% |
| Dec 31, 2023 | 28.98% |
| Sep 30, 2023 | 36.31% |
| Jun 30, 2023 | 28.31% |
| Mar 31, 2023 | 18.09% |
| Dec 31, 2022 | 15.71% |
| Sep 30, 2022 | 9.15% |
| Jun 30, 2022 | 17.46% |
| Mar 31, 2022 | -6.68% |
| Sep 30, 2021 | -4.42% |
| Jun 30, 2021 | 3.66% |
| Mar 31, 2021 | -12.66% |
| Dec 31, 2020 | 62.09% |